Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27121335,tmax,"Sumatriptan achieved Cmax rapidly (median tmax : 0.8-1.5 hours for adolescents, 0.5-2.0 hours for adults); elimination was also rapid (geometric mean t½ : <2 hours for adolescents, 1.9-2.4 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,0.8-1.5,2017,DB00669,Sumatriptan
,27121335,tmax,"Sumatriptan achieved Cmax rapidly (median tmax : 0.8-1.5 hours for adolescents, 0.5-2.0 hours for adults); elimination was also rapid (geometric mean t½ : <2 hours for adolescents, 1.9-2.4 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,0.5-2.0,2018,DB00669,Sumatriptan
<,27121335,t½,"Sumatriptan achieved Cmax rapidly (median tmax : 0.8-1.5 hours for adolescents, 0.5-2.0 hours for adults); elimination was also rapid (geometric mean t½ : <2 hours for adolescents, 1.9-2.4 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,2,2019,DB00669,Sumatriptan
,27121335,t½,"Sumatriptan achieved Cmax rapidly (median tmax : 0.8-1.5 hours for adolescents, 0.5-2.0 hours for adults); elimination was also rapid (geometric mean t½ : <2 hours for adolescents, 1.9-2.4 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,1.9-2.4,2020,DB00669,Sumatriptan
,27121335,tmax,"Compared with sumatriptan, naproxen was absorbed and eliminated more slowly (median tmax : 1.0-4.0 hours for adolescents, 1.0-3.0 hours for adults; geometric mean t½ : 13.4-16.3 hours for adolescents, 14.3-16.6 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,1.0-4.0,2021,DB00669,Sumatriptan
,27121335,tmax,"Compared with sumatriptan, naproxen was absorbed and eliminated more slowly (median tmax : 1.0-4.0 hours for adolescents, 1.0-3.0 hours for adults; geometric mean t½ : 13.4-16.3 hours for adolescents, 14.3-16.6 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,1.0-3.0,2022,DB00669,Sumatriptan
,27121335,t½,"Compared with sumatriptan, naproxen was absorbed and eliminated more slowly (median tmax : 1.0-4.0 hours for adolescents, 1.0-3.0 hours for adults; geometric mean t½ : 13.4-16.3 hours for adolescents, 14.3-16.6 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,13.4-16.3,2023,DB00669,Sumatriptan
,27121335,t½,"Compared with sumatriptan, naproxen was absorbed and eliminated more slowly (median tmax : 1.0-4.0 hours for adolescents, 1.0-3.0 hours for adults; geometric mean t½ : 13.4-16.3 hours for adolescents, 14.3-16.6 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,14.3-16.6,2024,DB00669,Sumatriptan
,1321655,Cmax,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),[ng] / [ml],82.3,8593,DB00669,Sumatriptan
,1321655,Cmax,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),[ng] / [ml],81.4,8594,DB00669,Sumatriptan
,1321655,AUC,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),[h·ng] / [ml],368,8595,DB00669,Sumatriptan
,1321655,AUC,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),[ng] / [ml],360,8596,DB00669,Sumatriptan
,1321655,elimination half-life,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),h,2.2,8597,DB00669,Sumatriptan
,1321655,elimination half-life,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),h,2.4,8598,DB00669,Sumatriptan
,28597922,t1/2,"Sumatriptan plasma concentrations peaked with DFN-02 between 10 and 15 minutes postdose, declining thereafter, with a t1/2 of about 2.5 hours; mean Cmax and AUC0-∞ values increased linearly across doses.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),h,2.5,8948,DB00669,Sumatriptan
,28597922,Cmax,"After DFN-02 doses of 5, 10, and 15 mg, mean Cmax was 40.7 ± 14.2, 71.2 ± 22.1, and 101.0 ± 49.5 ng/mL, and mean AUC0-∞ was 49.9 ± 20.6, 87.1 ± 31.2, and 120.5 ± 53.3 ng·h/mL, respectively.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),[ng] / [ml],40.7,8949,DB00669,Sumatriptan
,28597922,Cmax,"After DFN-02 doses of 5, 10, and 15 mg, mean Cmax was 40.7 ± 14.2, 71.2 ± 22.1, and 101.0 ± 49.5 ng/mL, and mean AUC0-∞ was 49.9 ± 20.6, 87.1 ± 31.2, and 120.5 ± 53.3 ng·h/mL, respectively.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),[ng] / [ml],71.2,8950,DB00669,Sumatriptan
,28597922,Cmax,"After DFN-02 doses of 5, 10, and 15 mg, mean Cmax was 40.7 ± 14.2, 71.2 ± 22.1, and 101.0 ± 49.5 ng/mL, and mean AUC0-∞ was 49.9 ± 20.6, 87.1 ± 31.2, and 120.5 ± 53.3 ng·h/mL, respectively.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),[ng] / [ml],101.0,8951,DB00669,Sumatriptan
,28597922,AUC0-∞,"After DFN-02 doses of 5, 10, and 15 mg, mean Cmax was 40.7 ± 14.2, 71.2 ± 22.1, and 101.0 ± 49.5 ng/mL, and mean AUC0-∞ was 49.9 ± 20.6, 87.1 ± 31.2, and 120.5 ± 53.3 ng·h/mL, respectively.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),[h·ng] / [ml],49.9,8952,DB00669,Sumatriptan
,28597922,AUC0-∞,"After DFN-02 doses of 5, 10, and 15 mg, mean Cmax was 40.7 ± 14.2, 71.2 ± 22.1, and 101.0 ± 49.5 ng/mL, and mean AUC0-∞ was 49.9 ± 20.6, 87.1 ± 31.2, and 120.5 ± 53.3 ng·h/mL, respectively.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),[h·ng] / [ml],87.1,8953,DB00669,Sumatriptan
,28597922,AUC0-∞,"After DFN-02 doses of 5, 10, and 15 mg, mean Cmax was 40.7 ± 14.2, 71.2 ± 22.1, and 101.0 ± 49.5 ng/mL, and mean AUC0-∞ was 49.9 ± 20.6, 87.1 ± 31.2, and 120.5 ± 53.3 ng·h/mL, respectively.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),[h·ng] / [ml],120.5,8954,DB00669,Sumatriptan
,28597922,Tmax,"Based on the established PK of a 6-mg subcutaneous sumatriptan injection (mean Tmax , 12 minutes; mean Cmax , 74 ± 15 ng/mL in the deltoid area of the arm) and the peak and time to peak sumatriptan concentrations of the DFN-02 doses tested, a 10-mg dose of DFN-02 was found to be the closest match.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),min,12,8955,DB00669,Sumatriptan
,28597922,Cmax,"Based on the established PK of a 6-mg subcutaneous sumatriptan injection (mean Tmax , 12 minutes; mean Cmax , 74 ± 15 ng/mL in the deltoid area of the arm) and the peak and time to peak sumatriptan concentrations of the DFN-02 doses tested, a 10-mg dose of DFN-02 was found to be the closest match.","Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597922/),[ng] / [ml],74,8956,DB00669,Sumatriptan
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,2 to 4,14164,DB00669,Sumatriptan
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,7 to 15,14165,DB00669,Sumatriptan
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,1,14166,DB00669,Sumatriptan
,25597782,bioavailability,Sumatriptan succinate (SS) is a 5-HT1 receptor agonist used in the treatment of migraine having poor bioavailability (15%) due to its extensive first-pass effect.,Sumatriptan succinate sublingual fast dissolving thin films: formulation and in vitro/in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25597782/),%,15,14265,DB00669,Sumatriptan
,25597782,tmax,Pharmacokinetic study of the optimum formula F7 (PVP K30:SS (1:1 w/w)) in healthy human volunteers using LC/MS/MS revealed a shorter tmax (0.25 h) compared to Imitrex® tablet 25 mg (2 h) which is considered promising especially for the rapid relief of acute migraine attacks.,Sumatriptan succinate sublingual fast dissolving thin films: formulation and in vitro/in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25597782/),h,0.25,14266,DB00669,Sumatriptan
,25597782,tmax,Pharmacokinetic study of the optimum formula F7 (PVP K30:SS (1:1 w/w)) in healthy human volunteers using LC/MS/MS revealed a shorter tmax (0.25 h) compared to Imitrex® tablet 25 mg (2 h) which is considered promising especially for the rapid relief of acute migraine attacks.,Sumatriptan succinate sublingual fast dissolving thin films: formulation and in vitro/in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25597782/),h,2,14267,DB00669,Sumatriptan
,11045888,peak serum concentration,The mean peak serum concentration following the 0700 h administration (Cmax; 59.09 +/- 10.53 ng mL(-1)) was significantly (P < 0.05; n = 12) higher than after the 1900 h administration (Cmax 41.88 +/- 12.21 ngmL(-1)).,Chronopharmacokinetics of sumatriptan in healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),[ng] / [ml],59.09,19119,DB00669,Sumatriptan
,11045888,Cmax,The mean peak serum concentration following the 0700 h administration (Cmax; 59.09 +/- 10.53 ng mL(-1)) was significantly (P < 0.05; n = 12) higher than after the 1900 h administration (Cmax 41.88 +/- 12.21 ngmL(-1)).,Chronopharmacokinetics of sumatriptan in healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),[ng] / [ml],59.09,19120,DB00669,Sumatriptan
,11045888,Cmax,The mean peak serum concentration following the 0700 h administration (Cmax; 59.09 +/- 10.53 ng mL(-1)) was significantly (P < 0.05; n = 12) higher than after the 1900 h administration (Cmax 41.88 +/- 12.21 ngmL(-1)).,Chronopharmacokinetics of sumatriptan in healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),1/[ngml],41.88,19121,DB00669,Sumatriptan
,11045888,oral clearance (CLs/f,"Following administration at 0700 h, the mean oral clearance (CLs/f; 781 +/- 186 mL h(- 1) kg(-1)) and the apparent volume of distribution (Vd/f; 2,379 +/- 684) were significantly lower (P < 0.05; n = 12) than after the 1900 h administration (CLs/f 1,208 +/- 458 mL h(-1) kg(-1), Vd/f 4,655 +/- 2,096 mL kg(-1)).",Chronopharmacokinetics of sumatriptan in healthy human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),[1·h(-·ml] / [kg],781,19122,DB00669,Sumatriptan
,11045888,apparent volume of distribution (Vd/f,"Following administration at 0700 h, the mean oral clearance (CLs/f; 781 +/- 186 mL h(- 1) kg(-1)) and the apparent volume of distribution (Vd/f; 2,379 +/- 684) were significantly lower (P < 0.05; n = 12) than after the 1900 h administration (CLs/f 1,208 +/- 458 mL h(-1) kg(-1), Vd/f 4,655 +/- 2,096 mL kg(-1)).",Chronopharmacokinetics of sumatriptan in healthy human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),,"2,379",19123,DB00669,Sumatriptan
,11045888,CLs/f,"Following administration at 0700 h, the mean oral clearance (CLs/f; 781 +/- 186 mL h(- 1) kg(-1)) and the apparent volume of distribution (Vd/f; 2,379 +/- 684) were significantly lower (P < 0.05; n = 12) than after the 1900 h administration (CLs/f 1,208 +/- 458 mL h(-1) kg(-1), Vd/f 4,655 +/- 2,096 mL kg(-1)).",Chronopharmacokinetics of sumatriptan in healthy human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),[ml] / [h·kg],"1,208",19124,DB00669,Sumatriptan
,11045888,Vd/f,"Following administration at 0700 h, the mean oral clearance (CLs/f; 781 +/- 186 mL h(- 1) kg(-1)) and the apparent volume of distribution (Vd/f; 2,379 +/- 684) were significantly lower (P < 0.05; n = 12) than after the 1900 h administration (CLs/f 1,208 +/- 458 mL h(-1) kg(-1), Vd/f 4,655 +/- 2,096 mL kg(-1)).",Chronopharmacokinetics of sumatriptan in healthy human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),[ml] / [kg],"4,655",19125,DB00669,Sumatriptan
,11045888,Vd/f,"The mean Vd/f value was again lower after the 1300h administration than after the 1900 h administration (2,763 +/- 1,417 vs 4,655 +/- 2,096 mL kg(-1); P < 0.05; n = 12).",Chronopharmacokinetics of sumatriptan in healthy human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),[ml] / [kg],"2,763",19126,DB00669,Sumatriptan
,11045888,Vd/f,"The mean Vd/f value was again lower after the 1300h administration than after the 1900 h administration (2,763 +/- 1,417 vs 4,655 +/- 2,096 mL kg(-1); P < 0.05; n = 12).",Chronopharmacokinetics of sumatriptan in healthy human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045888/),[ml] / [kg],"4,655",19127,DB00669,Sumatriptan
,21223633,flow-rate,"The chromatographic separation is achieved on ACE C18 (50 mm × 2.1 mm, 5 μm) analytical column under isocratic conditions, using 0.1% acetic acid and acetonitrile (15:85, v/v) at a flow-rate of 0.4 mL/min.",Development and validation of a sensitive and rapid method to determine naratriptan in human plasma by LC-ESI-MS-MS: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223633/),[ml] / [min],0.4,19177,DB00669,Sumatriptan
,1653135,Bioavailability,Bioavailability was nearly 100% after subcutaneous administration and averaged 14% after oral administration.,"The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653135/),%,100,23503,DB00669,Sumatriptan
,1653135,Bioavailability,Bioavailability was nearly 100% after subcutaneous administration and averaged 14% after oral administration.,"The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653135/),%,14,23504,DB00669,Sumatriptan
,1653135,plasma half-lives,The plasma half-lives of sumatriptan and the metabolite were about 2 h.,"The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653135/),h,2,23505,DB00669,Sumatriptan
,21545233,lengths,The mean lengths of DMs were 496.6 ± 2.9 μm for h-DM and 494.5 ± 1.3 μm for d-DM.,Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),μm,496.6,33612,DB00669,Sumatriptan
,21545233,lengths,The mean lengths of DMs were 496.6 ± 2.9 μm for h-DM and 494.5 ± 1.3 μm for d-DM.,Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),μm,494.5,33613,DB00669,Sumatriptan
,21545233,maximum plasma ST concentrations,"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[ng] / [ml],44.6,33614,DB00669,Sumatriptan
,21545233,maximum plasma ST concentrations,"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[ng] / [ml],38.4,33615,DB00669,Sumatriptan
,21545233,Cmax,"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[h·ng] / [ml],24.6,33616,DB00669,Sumatriptan
,21545233,Cmax,"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[ng] / [ml],38.4,33617,DB00669,Sumatriptan
,21545233,areas under the plasma ST concentration versus time curves (AUC),"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[h·ng] / [ml],24.6,33618,DB00669,Sumatriptan
,21545233,areas under the plasma ST concentration versus time curves (AUC),"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[h·ng] / [ml],14.1,33619,DB00669,Sumatriptan
,21545233,bioavailabilities,The bioavailabilities of ST from DMs were calculated as 100.7 ± 18.8% for h-DM and 93.6 ± 10.2% for d-DM.,Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),%,100.7,33620,DB00669,Sumatriptan
,21545233,bioavailabilities,The bioavailabilities of ST from DMs were calculated as 100.7 ± 18.8% for h-DM and 93.6 ± 10.2% for d-DM.,Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),%,93.6,33621,DB00669,Sumatriptan
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,64,36555,DB00669,Sumatriptan
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,67,36556,DB00669,Sumatriptan
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,50,36557,DB00669,Sumatriptan
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,53,36558,DB00669,Sumatriptan
,25488888,Фmax1B,"Our calculations showed that Фmax1B and Фmax1D were relatively high at 32.0-89.4% and 68.4-96.2%, respectively, suggesting that it is likely that a high occupancy is necessary to attain the clinical effect.",Theory-based analysis of clinical efficacy of triptans using receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488888/),%,32.0-89.4,43895,DB00669,Sumatriptan
,25488888,Фmax,"Our calculations showed that Фmax1B and Фmax1D were relatively high at 32.0-89.4% and 68.4-96.2%, respectively, suggesting that it is likely that a high occupancy is necessary to attain the clinical effect.",Theory-based analysis of clinical efficacy of triptans using receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488888/),%,32.0-89.4,43896,DB00669,Sumatriptan
higher,23411017,extraction recovery,The mean extraction recovery for sumatriptan was higher than 62.3%.,Rapid determination of sumatriptan in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411017/),%,62.3,44124,DB00669,Sumatriptan
,23411017,area under the plasma concentration-time curve from time 0 to 12 h,"After oral administration of 50-mg sumatriptan and serial blood sampling over 12 h, the mean area under the plasma concentration-time curve from time 0 to 12 h and the maximum plasma concentration were 116.2 ng h/mL and 33.2 ng/mL, respectively.",Rapid determination of sumatriptan in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411017/),[h·ng] / [ml],116.2,44125,DB00669,Sumatriptan
,23411017,maximum plasma concentration,"After oral administration of 50-mg sumatriptan and serial blood sampling over 12 h, the mean area under the plasma concentration-time curve from time 0 to 12 h and the maximum plasma concentration were 116.2 ng h/mL and 33.2 ng/mL, respectively.",Rapid determination of sumatriptan in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411017/),[ng] / [ml],33.2,44126,DB00669,Sumatriptan
,15051742,maximum concentration,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),[ng] / [ml],8.1,50764,DB00669,Sumatriptan
,15051742,maximum concentration,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),[ng] / [ml],10.8,50765,DB00669,Sumatriptan
,15051742,maximum concentration,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),[ng] / [ml],12.3,50766,DB00669,Sumatriptan
,15051742,half-life,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),h,1.4,50767,DB00669,Sumatriptan
,15051742,half-life,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),h,1.7,50768,DB00669,Sumatriptan
,15051742,half-life,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),h,1.7,50769,DB00669,Sumatriptan
,15051742,AUC,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),[h·ng] / [ml],27.8,50770,DB00669,Sumatriptan
,15051742,AUC,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),[h·ng] / [ml],42.4,50771,DB00669,Sumatriptan
,15051742,AUC,"The pharmacokinetic parameter estimates (geometric mean [95% confidence interval]) following 5, 10, and 20 mg sumatriptan were, respectively, as follows: maximum concentration = 8.1 ng/mL (3.6-18.4), 10.8 ng/mL (7.7-15.4), and 12.3 ng/mL (7.6-19.9); half-life = 1.4 hours (1.2-1.8), 1.7 hours (1.4-2.0), and 1.7 hours (1.3-2.3); and AUC = 27.8 ng*h/mL (9.7-79.8), 42.4 ng*h/mL (30.6-58.8), and 49.2 ng*h/mL (32.9-73.7).",Pharmacokinetics of sumatriptan nasal spray in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),[h·ng] / [ml],49.2,50772,DB00669,Sumatriptan
,15051742,time to maximum concentration,The median time to maximum concentration for all groups was 2 hours.,Pharmacokinetics of sumatriptan nasal spray in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),h,2,50773,DB00669,Sumatriptan
,15051742,Clearance (CL/F),"Clearance (CL/F) was 197 L/h for a 30-kg child with between-subject variability of 28%, and the volume of distribution was 751 L, normalized for an 11-year-old child with variability of 43%.",Pharmacokinetics of sumatriptan nasal spray in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),[l] / [h],197,50774,DB00669,Sumatriptan
,15051742,volume of distribution,"Clearance (CL/F) was 197 L/h for a 30-kg child with between-subject variability of 28%, and the volume of distribution was 751 L, normalized for an 11-year-old child with variability of 43%.",Pharmacokinetics of sumatriptan nasal spray in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051742/),l,751,50775,DB00669,Sumatriptan
,29203152,delivery rate,"A preparation, containing 30% by mass of PVP and 8.7mg sumatriptan, produced a delivery rate of 395±31μg/cm2h over a 7-hour period after a negligible lag time of approximately 39min.",Dissolving polyvinylpyrrolidone-based microneedle systems for in-vitro delivery of sumatriptan succinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29203152/),[μg] / [cm2h],395,54728,DB00669,Sumatriptan
,29203152,lag time,"A preparation, containing 30% by mass of PVP and 8.7mg sumatriptan, produced a delivery rate of 395±31μg/cm2h over a 7-hour period after a negligible lag time of approximately 39min.",Dissolving polyvinylpyrrolidone-based microneedle systems for in-vitro delivery of sumatriptan succinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29203152/),min,39,54729,DB00669,Sumatriptan
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00669,Sumatriptan
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00669,Sumatriptan
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00669,Sumatriptan
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00669,Sumatriptan
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00669,Sumatriptan
,7851052,Bioavailability,"Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism.",Sumatriptan clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),%,96,55552,DB00669,Sumatriptan
,7851052,Bioavailability,"Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism.",Sumatriptan clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),%,14,55553,DB00669,Sumatriptan
,7851052,elimination half-life,"Total plasma clearance is rapid, with an elimination half-life of around 2 hours.",Sumatriptan clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),h,2,55554,DB00669,Sumatriptan
,31991540,flow rate,"The separation was performed on a reversed-phase Symmetry® C18 column (150 × 4.6 mm i.d., 5 µm) under a gradient mode, using a 0.2% formic acid aqueous solution and acetonitrile at a flow rate of 0.5 mL/min.",Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Simple Analysis of Sumatriptan and its Application in Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31991540/),[ml] / [min],0.5,61867,DB00669,Sumatriptan
,9209775,tmax,"For all doses, the tmax of sumatriptan occurred within 2.5 h, and the t1/2 was approximately 2 h.","Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209775/),h,2.5,63296,DB00669,Sumatriptan
,9209775,t1/2,"For all doses, the tmax of sumatriptan occurred within 2.5 h, and the t1/2 was approximately 2 h.","Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209775/),h,2,63297,DB00669,Sumatriptan
,12856385,Cmax,"Noncompartmental pharmacokinetic parameters (geometric mean and 95% confidence interval) for the remaining 16 subjects were as follows: Cmax was 13.9 (11.0, 17.6) ng/mL, AUC infinity was 57.3 (47.6, 69.0) ng/mL.h, and t1/2 was 2.0 (1.8, 2.3) hours.",Pharmacokinetics of sumatriptan nasal spray in adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856385/),[ng] / [ml],13.9,67634,DB00669,Sumatriptan
,12856385,AUC infinity,"Noncompartmental pharmacokinetic parameters (geometric mean and 95% confidence interval) for the remaining 16 subjects were as follows: Cmax was 13.9 (11.0, 17.6) ng/mL, AUC infinity was 57.3 (47.6, 69.0) ng/mL.h, and t1/2 was 2.0 (1.8, 2.3) hours.",Pharmacokinetics of sumatriptan nasal spray in adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856385/),[ng] / [h·ml],57.3,67635,DB00669,Sumatriptan
,12856385,t1/2,"Noncompartmental pharmacokinetic parameters (geometric mean and 95% confidence interval) for the remaining 16 subjects were as follows: Cmax was 13.9 (11.0, 17.6) ng/mL, AUC infinity was 57.3 (47.6, 69.0) ng/mL.h, and t1/2 was 2.0 (1.8, 2.3) hours.",Pharmacokinetics of sumatriptan nasal spray in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856385/),h,2.0,67636,DB00669,Sumatriptan
,12856385,CL/F,"Population pharmacokinetic analysis for all subjects (n = 21) showed that clearance and volume of distribution increase slightly with age and body size, but the changes were minimal and would not warrant dose adjustment: CL/F was 316 L (coefficient of variance [CV] = 25%) and Vd/F was 1070 L (CV = 46%).",Pharmacokinetics of sumatriptan nasal spray in adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856385/),l,316,67637,DB00669,Sumatriptan
,12856385,Vd/F,"Population pharmacokinetic analysis for all subjects (n = 21) showed that clearance and volume of distribution increase slightly with age and body size, but the changes were minimal and would not warrant dose adjustment: CL/F was 316 L (coefficient of variance [CV] = 25%) and Vd/F was 1070 L (CV = 46%).",Pharmacokinetics of sumatriptan nasal spray in adolescents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856385/),l,1070,67638,DB00669,Sumatriptan
,8866921,milk:plasma ratio,"2. The mean milk:plasma ratio estimated from the areas under the milk and plasma concentration-time curves (AUC) was 4.9 (95% CI 4.1-5.7), indicating a significant transfer of sumatriptan into the milk compartment.",Distribution and excretion of sumatriptan in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866921/),,4,70896,DB00669,Sumatriptan
,8866921,total recovery of drug in milk,"3. The mean total recovery of drug in milk was estimated to be only 14.4 micrograms (95% CI 6.1-22.7 micrograms), or 0.24% of the 6 mg administered dose.",Distribution and excretion of sumatriptan in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866921/),μg,14.4,70897,DB00669,Sumatriptan
,8866921,total recovery of drug in milk,"3. The mean total recovery of drug in milk was estimated to be only 14.4 micrograms (95% CI 6.1-22.7 micrograms), or 0.24% of the 6 mg administered dose.",Distribution and excretion of sumatriptan in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866921/),%,0.24,70898,DB00669,Sumatriptan
,8866921,oral bioavailability,"4. If oral bioavailability in the infant is similar to that in adults (14%), the weight-adjusted infant dose is reduced to 0.49%.",Distribution and excretion of sumatriptan in human milk. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866921/),%,14,70899,DB00669,Sumatriptan
,8539258,elimination half-life,"Given the average elimination half-life of 2 hr for sumatriptan, it is evident that only very small amounts of the agent will cross from mother to fetus after single doses of Imitrex.",Sumatriptan (Imitrex) transport by the human placenta. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8539258/),h,2,71132,DB00669,Sumatriptan
,17182233,cumulative delivery,"It was found in vitro that increasing drug load in the patch from 9.7 to 39 mg had no statistically significant effect on cumulative delivery (cf. 305.6+/-172.4 vs. 389.4+/-80.4 microg cm(-2), respectively).",In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17182233/),[μg] / [(cm)^2],305.6,71361,DB00669,Sumatriptan
,17182233,cumulative delivery,"It was found in vitro that increasing drug load in the patch from 9.7 to 39 mg had no statistically significant effect on cumulative delivery (cf. 305.6+/-172.4 vs. 389.4+/-80.4 microg cm(-2), respectively).",In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17182233/),[μg] / [(cm)^2],389.4,71362,DB00669,Sumatriptan
,17182233,cumulative amount,"However, for a given drug load (39 mg) increasing formulation pH from pH 4.7 to 6.8 significantly increased the cumulative amount of sumatriptan delivered across the skin (389.4+/-80.4 vs. 652.4+/-94.2 microg cm(-2)).",In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17182233/),[μg] / [(cm)^2],389.4,71363,DB00669,Sumatriptan
,17182233,cumulative amount,"However, for a given drug load (39 mg) increasing formulation pH from pH 4.7 to 6.8 significantly increased the cumulative amount of sumatriptan delivered across the skin (389.4+/-80.4 vs. 652.4+/-94.2 microg cm(-2)).",In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17182233/),[μg] / [(cm)^2],652.4,71364,DB00669,Sumatriptan
<,28741429,tmax,"Median tmax was <20 min, comparable to subcutaneous sumatriptan.",Rapid systemic delivery of zolmitriptan using an adhesive dermally applied microarray. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741429/),min,20,75703,DB00669,Sumatriptan
,27038484,oral bioavailability,"Sumatriptan succinate (SS) is a selective serotonin receptor agonist used for the treatment of migraine attacks, suffering from extensive first-pass metabolism and low oral bioavailability (∼14%).",Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038484/),%,∼14,78481,DB00669,Sumatriptan
,27038484,disintegration times,"Results showed that tablets prepared using Pharmaburst® had significantly (p < 0.05) the lowest simulated wetting and in vitro disintegration times of 17.17 and 23.50 s, respectively, with Q 5 min of 83.62%.",Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038484/),s,17.17,78482,DB00669,Sumatriptan
,27038484,disintegration times,"Results showed that tablets prepared using Pharmaburst® had significantly (p < 0.05) the lowest simulated wetting and in vitro disintegration times of 17.17 and 23.50 s, respectively, with Q 5 min of 83.62%.",Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038484/),s,23.50,78483,DB00669,Sumatriptan
,27038484,Q 5 min,"Results showed that tablets prepared using Pharmaburst® had significantly (p < 0.05) the lowest simulated wetting and in vitro disintegration times of 17.17 and 23.50 s, respectively, with Q 5 min of 83.62%.",Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038484/),%,83.62,78484,DB00669,Sumatriptan
,27038484,the residence time,HPMC showed a significant (p < 0.05) increase in the residence time from 48.44 to 183.76 s.,Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038484/),s,48.44,78485,DB00669,Sumatriptan
,27038484,the residence time,HPMC showed a significant (p < 0.05) increase in the residence time from 48.44 to 183.76 s.,Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038484/),s,183.76,78486,DB00669,Sumatriptan
,27038484,relative bioavailability,The relative bioavailability was found to be equal to 132.34% relative to the oral tablet Imitrex®.,Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038484/),%,132.34,78487,DB00669,Sumatriptan
,16584167,globule size,SME and SSME were transparent and stable with mean globule size 38 +/- 20 nm and zeta potential between -35 to -55 mV.,Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584167/),nm,38,78575,DB00669,Sumatriptan
,16584167,Brain/blood uptake ratios,"Brain/blood uptake ratios at 0.5 hour following IV administration of SME and intranasal administrations of SME, SMME, and SSS were found to be 0.20, 0.50, 0.60, and 0.26, respectively, suggesting effective transport of drug following intranasal administration of microemulsions.",Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584167/),,0.20,78576,DB00669,Sumatriptan
,16584167,Brain/blood uptake ratios,"Brain/blood uptake ratios at 0.5 hour following IV administration of SME and intranasal administrations of SME, SMME, and SSS were found to be 0.20, 0.50, 0.60, and 0.26, respectively, suggesting effective transport of drug following intranasal administration of microemulsions.",Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584167/),,0.50,78577,DB00669,Sumatriptan
,16584167,Brain/blood uptake ratios,"Brain/blood uptake ratios at 0.5 hour following IV administration of SME and intranasal administrations of SME, SMME, and SSS were found to be 0.20, 0.50, 0.60, and 0.26, respectively, suggesting effective transport of drug following intranasal administration of microemulsions.",Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584167/),,0.60,78578,DB00669,Sumatriptan
,16584167,Brain/blood uptake ratios,"Brain/blood uptake ratios at 0.5 hour following IV administration of SME and intranasal administrations of SME, SMME, and SSS were found to be 0.20, 0.50, 0.60, and 0.26, respectively, suggesting effective transport of drug following intranasal administration of microemulsions.",Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584167/),,0.26,78579,DB00669,Sumatriptan
,26242873,occup,"For Ф1D, it was indicated that all triptans obtained an occupancy of 80% or higher at maximum.",Theoretical analysis of headache recurrence in patients administered triptans for migraine based on receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242873/),%,80,83156,DB00669,Sumatriptan
,28618340,flow rate,A simple isocratic separation mode was used with a mobile phase consisted of acetonitrile and 10mM phosphate buffer adjusted to pH 3.0 (20:80; v/v) at flow rate 1.0mLmin-1.,Fast and efficient zirconia-based reversed phase chromatography for selective determination of triptans in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618340/),1/[mlmin],1.0,86345,DB00669,Sumatriptan
,28618340,detection limits,The linearity range obtained for the developed HPLC method was 15-2000ngmL-1 with detection limits of 4.8- 6.2ngmL-1 for all the studied triptans.,Fast and efficient zirconia-based reversed phase chromatography for selective determination of triptans in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618340/),1/[ngml],4.8- 6.2,86346,DB00669,Sumatriptan
,23979809,Tmax,"Tmax was observed at 0.5 hours in 12 of 15 subjects with the extemporaneous suppository, compared with the range of 0.75 hours to 1.5 hours in 13 of 15 subjects with the oral tablet.",Pharmacokinetics in Healthy Volunteers of Sumatriptan 25-mg Oral Tablet Versus 25-mg Extemporaneous Suppository. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23979809/),h,0.5,88351,DB00669,Sumatriptan
,23979809,Tmax,"Tmax was observed at 0.5 hours in 12 of 15 subjects with the extemporaneous suppository, compared with the range of 0.75 hours to 1.5 hours in 13 of 15 subjects with the oral tablet.",Pharmacokinetics in Healthy Volunteers of Sumatriptan 25-mg Oral Tablet Versus 25-mg Extemporaneous Suppository. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23979809/),h,0.75,88352,DB00669,Sumatriptan
,23979809,Tmax,"Tmax was observed at 0.5 hours in 12 of 15 subjects with the extemporaneous suppository, compared with the range of 0.75 hours to 1.5 hours in 13 of 15 subjects with the oral tablet.",Pharmacokinetics in Healthy Volunteers of Sumatriptan 25-mg Oral Tablet Versus 25-mg Extemporaneous Suppository. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23979809/),h,1.5,88353,DB00669,Sumatriptan
,11422001,AUC,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[h·ng] / [ml],483,90332,DB00669,Sumatriptan
,11422001,AUC,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[h·ng] / [ml],352,90333,DB00669,Sumatriptan
,11422001,oral clearance,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[l] / [h],26.6,90334,DB00669,Sumatriptan
,11422001,oral clearance,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[l] / [h],36.6,90335,DB00669,Sumatriptan
,11422001,half-life,"Mean half-life was longer (4.22 +/- 0.78 vs 3.41 +/- 0.45 h, P = 0.0002) after coadministration with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),h,4.22,90336,DB00669,Sumatriptan
,11422001,half-life,"Mean half-life was longer (4.22 +/- 0.78 vs 3.41 +/- 0.45 h, P = 0.0002) after coadministration with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),h,3.41,90337,DB00669,Sumatriptan
,1379152,half-life,It is likely that migraine recurrence is related to the short half-life of the drug (approximately 2 hours).,"Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379152/),h,2,90807,DB00669,Sumatriptan
,31920290,bioavailability,SUT bioavailability is low (15%) when it is taken orally owing to its gastric breakdown and bloodstream before reaching the target arteries.,"Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31920290/),%,15,93290,DB00669,Sumatriptan
,31920290,percent entrapment efficiencies (%EE),"The prepared transferosomes exhibited percent entrapment efficiencies (%EE) of 40.41±3.02 to 77.47±2.85%, mean diameters of 97.25 to 245.01 nm, sustained drug release over 6 hours, and acceptable ex vivo permeation findings.","Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31920290/),%,40.41,93291,DB00669,Sumatriptan
,31920290,percent entrapment efficiencies (%EE),"The prepared transferosomes exhibited percent entrapment efficiencies (%EE) of 40.41±3.02 to 77.47±2.85%, mean diameters of 97.25 to 245.01 nm, sustained drug release over 6 hours, and acceptable ex vivo permeation findings.","Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31920290/),%,77.47,93292,DB00669,Sumatriptan
,19925626,absolute bioavailability,The absolute bioavailability of subcutaneous (s.c.) sumatriptan is 96-100%.,Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925626/),%,96-100,95163,DB00669,Sumatriptan
,19925626,T(max),"The decay curve for plasma concentration after 6 mg s.c. sumatriptan (ie, after T(max) = about 0.2 hours) includes a large distribution component.",Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925626/),h,0.2,95164,DB00669,Sumatriptan
,19925626,AUC(0-10h),"At t = 10 hours, the concentrations in both sets were <1 ng/mL (ie, below the lower limit of assay quantitation), and AUC(0-10h) was 97.4 and 117 ng.",Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925626/),ng,97.4,95165,DB00669,Sumatriptan
,19925626,AUC(0-10h),"At t = 10 hours, the concentrations in both sets were <1 ng/mL (ie, below the lower limit of assay quantitation), and AUC(0-10h) was 97.4 and 117 ng.",Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925626/),ng,117,95166,DB00669,Sumatriptan
,9408857,protein binding,"Through all species, the protein binding of sumatriptan is similar (14-16%), and its metabolic pathway undergoes extensive oxidative deamination involving the monoamine oxidase A isoenzyme.",Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408857/),%,14-16,109262,DB00669,Sumatriptan
,9408857,total clearance,"The kinetic parameters predicted in any species were close to the observed values by species: 77 L/hr vs. 80 L/hr in man for total clearance, 137 L vs. 119 L for distribution volume at steady state.",Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408857/),[l] / [h],77,109263,DB00669,Sumatriptan
,9408857,total clearance,"The kinetic parameters predicted in any species were close to the observed values by species: 77 L/hr vs. 80 L/hr in man for total clearance, 137 L vs. 119 L for distribution volume at steady state.",Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408857/),[l] / [h],80,109264,DB00669,Sumatriptan
,9408857,distribution volume at steady state,"The kinetic parameters predicted in any species were close to the observed values by species: 77 L/hr vs. 80 L/hr in man for total clearance, 137 L vs. 119 L for distribution volume at steady state.",Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408857/),l,137,109265,DB00669,Sumatriptan
,9408857,distribution volume at steady state,"The kinetic parameters predicted in any species were close to the observed values by species: 77 L/hr vs. 80 L/hr in man for total clearance, 137 L vs. 119 L for distribution volume at steady state.",Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408857/),l,119,109266,DB00669,Sumatriptan
,10636142,headache response rates,"At the primary endpoint (2 hours after dosing), headache response rates were 24% (30/126) for placebo; 55% (63/115) for sumatriptan, 100 mg; 54% (70/129) for eletriptan, 20 mg; 65% (76/117) for eletriptan, 40 mg; and 77% (91/118) for eletriptan, 80 mg.","Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10636142/),%,24,109837,DB00669,Sumatriptan
,10636142,headache response rates,"At the primary endpoint (2 hours after dosing), headache response rates were 24% (30/126) for placebo; 55% (63/115) for sumatriptan, 100 mg; 54% (70/129) for eletriptan, 20 mg; 65% (76/117) for eletriptan, 40 mg; and 77% (91/118) for eletriptan, 80 mg.","Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10636142/),%,55,109838,DB00669,Sumatriptan
,10636142,headache response rates,"At the primary endpoint (2 hours after dosing), headache response rates were 24% (30/126) for placebo; 55% (63/115) for sumatriptan, 100 mg; 54% (70/129) for eletriptan, 20 mg; 65% (76/117) for eletriptan, 40 mg; and 77% (91/118) for eletriptan, 80 mg.","Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10636142/),%,54,109839,DB00669,Sumatriptan
,10636142,headache response rates,"At the primary endpoint (2 hours after dosing), headache response rates were 24% (30/126) for placebo; 55% (63/115) for sumatriptan, 100 mg; 54% (70/129) for eletriptan, 20 mg; 65% (76/117) for eletriptan, 40 mg; and 77% (91/118) for eletriptan, 80 mg.","Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10636142/),%,65,109840,DB00669,Sumatriptan
,19549162,T(max),The first T(max) was usually about 10-15 minutes.,"Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19549162/),min,10-15,111743,DB00669,Sumatriptan
,25530963,lag time,"From results, it can be concluded that optimized batch F8 containing polyox WSR205 (72.72%) and xanthan gum (27.27%) of total weight of polymer has shown floating lag time of 55 ± 2 sec, drug content of 100.35 ± 0.4%, hardness of 6 ± 0.1 Kg/cm(2), and 98.69 ± 2% drug release in pulse manner with lag time of 7 ± 0.1 h.",Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25530963/),s,55,113036,DB00669,Sumatriptan
,25530963,hardness,"From results, it can be concluded that optimized batch F8 containing polyox WSR205 (72.72%) and xanthan gum (27.27%) of total weight of polymer has shown floating lag time of 55 ± 2 sec, drug content of 100.35 ± 0.4%, hardness of 6 ± 0.1 Kg/cm(2), and 98.69 ± 2% drug release in pulse manner with lag time of 7 ± 0.1 h.",Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25530963/),[kg] / [cm],6,113037,DB00669,Sumatriptan
,25530963,lag time,"From results, it can be concluded that optimized batch F8 containing polyox WSR205 (72.72%) and xanthan gum (27.27%) of total weight of polymer has shown floating lag time of 55 ± 2 sec, drug content of 100.35 ± 0.4%, hardness of 6 ± 0.1 Kg/cm(2), and 98.69 ± 2% drug release in pulse manner with lag time of 7 ± 0.1 h.",Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25530963/),h,7,113038,DB00669,Sumatriptan
,9056052,tmax,"MK-462 was rapidly absorbed with a median tmax of 1.3 h (range 1-3 h) vs a tmax for sumatriptan of 2.5 h (range 1-4 h, P < 0.001).",Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056052/),h,1.3,115982,DB00669,Sumatriptan
,9056052,tmax,"MK-462 was rapidly absorbed with a median tmax of 1.3 h (range 1-3 h) vs a tmax for sumatriptan of 2.5 h (range 1-4 h, P < 0.001).",Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056052/),h,2.5,115983,DB00669,Sumatriptan
,9209776,elimination half-life (t1/2),"The elimination half-life (t1/2), approximately 2 h, was unaffected by the magnitude of dose.","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),h,2,123632,DB00669,Sumatriptan
,9209776,Cmax,"Day 4 values were significantly higher (p < or = 0.05) for Cmax (16.9 ng/ml vs 13.1 ng/ml), renal clearance (Clr; 19.0 l/h vs 14.2 l/h), and t1/2 (2.18 h vs 1.93 h), and shorter for tmax (0.88 h vs 1.75 h).","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),[ng] / [ml],16.9,123633,DB00669,Sumatriptan
,9209776,Cmax,"Day 4 values were significantly higher (p < or = 0.05) for Cmax (16.9 ng/ml vs 13.1 ng/ml), renal clearance (Clr; 19.0 l/h vs 14.2 l/h), and t1/2 (2.18 h vs 1.93 h), and shorter for tmax (0.88 h vs 1.75 h).","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),[ng] / [ml],13.1,123634,DB00669,Sumatriptan
,9209776,renal clearance (Clr,"Day 4 values were significantly higher (p < or = 0.05) for Cmax (16.9 ng/ml vs 13.1 ng/ml), renal clearance (Clr; 19.0 l/h vs 14.2 l/h), and t1/2 (2.18 h vs 1.93 h), and shorter for tmax (0.88 h vs 1.75 h).","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),[l] / [h],19.0,123635,DB00669,Sumatriptan
,9209776,renal clearance (Clr,"Day 4 values were significantly higher (p < or = 0.05) for Cmax (16.9 ng/ml vs 13.1 ng/ml), renal clearance (Clr; 19.0 l/h vs 14.2 l/h), and t1/2 (2.18 h vs 1.93 h), and shorter for tmax (0.88 h vs 1.75 h).","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),[l] / [h],14.2,123636,DB00669,Sumatriptan
,9209776,t1/2,"Day 4 values were significantly higher (p < or = 0.05) for Cmax (16.9 ng/ml vs 13.1 ng/ml), renal clearance (Clr; 19.0 l/h vs 14.2 l/h), and t1/2 (2.18 h vs 1.93 h), and shorter for tmax (0.88 h vs 1.75 h).","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),h,2.18,123637,DB00669,Sumatriptan
,9209776,t1/2,"Day 4 values were significantly higher (p < or = 0.05) for Cmax (16.9 ng/ml vs 13.1 ng/ml), renal clearance (Clr; 19.0 l/h vs 14.2 l/h), and t1/2 (2.18 h vs 1.93 h), and shorter for tmax (0.88 h vs 1.75 h).","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),h,1.93,123638,DB00669,Sumatriptan
,9209776,tmax,"Day 4 values were significantly higher (p < or = 0.05) for Cmax (16.9 ng/ml vs 13.1 ng/ml), renal clearance (Clr; 19.0 l/h vs 14.2 l/h), and t1/2 (2.18 h vs 1.93 h), and shorter for tmax (0.88 h vs 1.75 h).","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),h,0.88,123639,DB00669,Sumatriptan
,9209776,tmax,"Day 4 values were significantly higher (p < or = 0.05) for Cmax (16.9 ng/ml vs 13.1 ng/ml), renal clearance (Clr; 19.0 l/h vs 14.2 l/h), and t1/2 (2.18 h vs 1.93 h), and shorter for tmax (0.88 h vs 1.75 h).","Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209776/),h,1.75,123640,DB00669,Sumatriptan
,11327198,bioavailability,"For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan).",Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327198/),%,14,123788,DB00669,Sumatriptan
,11327198,bioavailability,"For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan).",Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327198/),%,74,123789,DB00669,Sumatriptan
,11327198,elimination half-life,"For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan).",Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327198/),h,2,123790,DB00669,Sumatriptan
,11327198,elimination half-life,"For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan).",Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327198/),h,25,123791,DB00669,Sumatriptan
,27613076,tmax,"In the comparison with commercially available intranasal sumatriptan 20 mg, DFN-02 had a more rapid absorption profile; tmax was 15 minutes for DFN-02 monodose, 10.2 minutes for DFN-02 multidose, and 2.0 hours for commercially available intranasal sumatriptan 20 mg.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),min,15,123903,DB00669,Sumatriptan
,27613076,tmax,"In the comparison with commercially available intranasal sumatriptan 20 mg, DFN-02 had a more rapid absorption profile; tmax was 15 minutes for DFN-02 monodose, 10.2 minutes for DFN-02 multidose, and 2.0 hours for commercially available intranasal sumatriptan 20 mg.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),min,10.2,123904,DB00669,Sumatriptan
,27613076,tmax,"In the comparison with commercially available intranasal sumatriptan 20 mg, DFN-02 had a more rapid absorption profile; tmax was 15 minutes for DFN-02 monodose, 10.2 minutes for DFN-02 multidose, and 2.0 hours for commercially available intranasal sumatriptan 20 mg.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),h,2.0,123905,DB00669,Sumatriptan
,27613076,tmax,"Compared with 4 and 6 mg subcutaneous sumatriptan, DFN-02's median tmax (10 minutes) was significantly earlier (15 minutes; P < .0001).","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),min,10,123906,DB00669,Sumatriptan
,27613076,tmax,"Compared with 4 and 6 mg subcutaneous sumatriptan, DFN-02's median tmax (10 minutes) was significantly earlier (15 minutes; P < .0001).","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),min,15,123907,DB00669,Sumatriptan
,27613076,AUC0-2,"Mean sumatriptan exposure metrics were similar for DFN-02 and 4 mg sumatriptan: AUC0-2 : 35.12 and 44.82 ng*hour/mL, respectively; AUC0-∞ : 60.70 and 69.21 ng*hour/mL, respectively; Cmax : 51.79 and 49.07 ng/mL, respectively.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[h·ng] / [ml],35.12,123908,DB00669,Sumatriptan
,27613076,AUC0-2,"Mean sumatriptan exposure metrics were similar for DFN-02 and 4 mg sumatriptan: AUC0-2 : 35.12 and 44.82 ng*hour/mL, respectively; AUC0-∞ : 60.70 and 69.21 ng*hour/mL, respectively; Cmax : 51.79 and 49.07 ng/mL, respectively.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[h·ng] / [ml],44.82,123909,DB00669,Sumatriptan
,27613076,AUC0-∞,"Mean sumatriptan exposure metrics were similar for DFN-02 and 4 mg sumatriptan: AUC0-2 : 35.12 and 44.82 ng*hour/mL, respectively; AUC0-∞ : 60.70 and 69.21 ng*hour/mL, respectively; Cmax : 51.79 and 49.07 ng/mL, respectively.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[h·ng] / [ml],60.70,123910,DB00669,Sumatriptan
,27613076,AUC0-∞,"Mean sumatriptan exposure metrics were similar for DFN-02 and 4 mg sumatriptan: AUC0-2 : 35.12 and 44.82 ng*hour/mL, respectively; AUC0-∞ : 60.70 and 69.21 ng*hour/mL, respectively; Cmax : 51.79 and 49.07 ng/mL, respectively.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[h·ng] / [ml],69.21,123911,DB00669,Sumatriptan
,27613076,Cmax,"Mean sumatriptan exposure metrics were similar for DFN-02 and 4 mg sumatriptan: AUC0-2 : 35.12 and 44.82 ng*hour/mL, respectively; AUC0-∞ : 60.70 and 69.21 ng*hour/mL, respectively; Cmax : 51.79 and 49.07 ng/mL, respectively.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[ng] / [ml],51.79,123912,DB00669,Sumatriptan
,27613076,Cmax,"Mean sumatriptan exposure metrics were similar for DFN-02 and 4 mg sumatriptan: AUC0-2 : 35.12 and 44.82 ng*hour/mL, respectively; AUC0-∞ : 60.70 and 69.21 ng*hour/mL, respectively; Cmax : 51.79 and 49.07 ng/mL, respectively.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[ng] / [ml],49.07,123913,DB00669,Sumatriptan
,27613076,AUC0-2,"With 6 mg subcutaneous sumatriptan, these exposure metrics were about 50% larger (AUC0-2 : 67.17 ng*hour/mL; AUC0-∞ : 103.78 ng*hour/mL; Cmax : 72.75 ng/mL).","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[h·ng] / [ml],67.17,123914,DB00669,Sumatriptan
,27613076,AUC0-∞,"With 6 mg subcutaneous sumatriptan, these exposure metrics were about 50% larger (AUC0-2 : 67.17 ng*hour/mL; AUC0-∞ : 103.78 ng*hour/mL; Cmax : 72.75 ng/mL).","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[h·ng] / [ml],103.78,123915,DB00669,Sumatriptan
,27613076,Cmax,"With 6 mg subcutaneous sumatriptan, these exposure metrics were about 50% larger (AUC0-2 : 67.17 ng*hour/mL; AUC0-∞ : 103.78 ng*hour/mL; Cmax : 72.75 ng/mL).","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[ng] / [ml],72.75,123916,DB00669,Sumatriptan
,27613076,Cmax,"DDM exposure was low (mean Cmax : 1.63 ng/mL), tmax was 30 minutes, and it was undetectable by 4 hours.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),[ng] / [ml],1.63,123917,DB00669,Sumatriptan
,27613076,tmax,"DDM exposure was low (mean Cmax : 1.63 ng/mL), tmax was 30 minutes, and it was undetectable by 4 hours.","A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613076/),min,30,123918,DB00669,Sumatriptan
,15311727,half-life,"Additionally, frovatriptan has a half-life of approximately 25 h, substantially longer than that of any other agent within its class.","Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15311727/),h,25,126571,DB00669,Sumatriptan
,15311727,headache response rates,"At 2h, headache response rates for frovatriptan 2.5 mg ranged from 38 to 40% compared to 22-35% for placebo.","Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15311727/),%,38 to 40,126572,DB00669,Sumatriptan
,15311727,headache response rates,"At 2h, headache response rates for frovatriptan 2.5 mg ranged from 38 to 40% compared to 22-35% for placebo.","Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15311727/),%,22-35,126573,DB00669,Sumatriptan
,10567953,total clearance,The total clearance and the distribution volume at steady state were 71.2 L/hr and 94.5 L after i.v. dosing and 68.7 L/hr and 109 L after inclusion of the s.c. and po data.,Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10567953/),[l] / [h],71.2,131082,DB00669,Sumatriptan
,10567953,total clearance,The total clearance and the distribution volume at steady state were 71.2 L/hr and 94.5 L after i.v. dosing and 68.7 L/hr and 109 L after inclusion of the s.c. and po data.,Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10567953/),[l] / [h],68.7,131083,DB00669,Sumatriptan
,10567953,distribution volume at steady state,The total clearance and the distribution volume at steady state were 71.2 L/hr and 94.5 L after i.v. dosing and 68.7 L/hr and 109 L after inclusion of the s.c. and po data.,Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10567953/),l,94.5,131084,DB00669,Sumatriptan
,10567953,distribution volume at steady state,The total clearance and the distribution volume at steady state were 71.2 L/hr and 94.5 L after i.v. dosing and 68.7 L/hr and 109 L after inclusion of the s.c. and po data.,Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10567953/),l,109,131085,DB00669,Sumatriptan
,9210982,overall bioavailability,The overall bioavailability of sumatriptan was 40-50%.,"off absorption, pharmacodynamics, metabolism and excretion of 14C-sumatriptan following intranasal administration to the beagle dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210982/),%,40-50,131766,DB00669,Sumatriptan
,9210982,half-life,Sumatriptan was eliminated from plasma with a half-life of 1.5 or 1.9 h after intravenous or intranasal dosage respectively.,"off absorption, pharmacodynamics, metabolism and excretion of 14C-sumatriptan following intranasal administration to the beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210982/),h,1.5,131767,DB00669,Sumatriptan
,9210982,half-life,Sumatriptan was eliminated from plasma with a half-life of 1.5 or 1.9 h after intravenous or intranasal dosage respectively.,"off absorption, pharmacodynamics, metabolism and excretion of 14C-sumatriptan following intranasal administration to the beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210982/),h,1.9,131768,DB00669,Sumatriptan
,27474357,Cmax,"When compared with historical adult data, adolescent patients demonstrated similar systemic exposures to those observed in adults (mean Cmax 20.20 (±6.43) ng/mL in adolescents vs 21.89 (±6.15) ng/mL in adults; mean AUC0-∞ 98.1 (±28.1) ng·h/mL in adolescents vs 109.7 (±26.1) ng·h/mL in adults).","A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474357/),[ng] / [ml],20.20,138989,DB00669,Sumatriptan
,27474357,Cmax,"When compared with historical adult data, adolescent patients demonstrated similar systemic exposures to those observed in adults (mean Cmax 20.20 (±6.43) ng/mL in adolescents vs 21.89 (±6.15) ng/mL in adults; mean AUC0-∞ 98.1 (±28.1) ng·h/mL in adolescents vs 109.7 (±26.1) ng·h/mL in adults).","A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474357/),[ng] / [ml],21.89,138990,DB00669,Sumatriptan
,27474357,AUC0-∞,"When compared with historical adult data, adolescent patients demonstrated similar systemic exposures to those observed in adults (mean Cmax 20.20 (±6.43) ng/mL in adolescents vs 21.89 (±6.15) ng/mL in adults; mean AUC0-∞ 98.1 (±28.1) ng·h/mL in adolescents vs 109.7 (±26.1) ng·h/mL in adults).","A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474357/),[h·ng] / [ml],98.1,138991,DB00669,Sumatriptan
,27474357,AUC0-∞,"When compared with historical adult data, adolescent patients demonstrated similar systemic exposures to those observed in adults (mean Cmax 20.20 (±6.43) ng/mL in adolescents vs 21.89 (±6.15) ng/mL in adults; mean AUC0-∞ 98.1 (±28.1) ng·h/mL in adolescents vs 109.7 (±26.1) ng·h/mL in adults).","A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474357/),[h·ng] / [ml],109.7,138992,DB00669,Sumatriptan
,7768259,subcutaneous bioavailability,The mean subcutaneous bioavailability is 96% compared to 14% for the oral tablet.,Single dose pharmacokinetics of sumatriptan in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768259/),%,96,139885,DB00669,Sumatriptan
,7768259,subcutaneous bioavailability,The mean subcutaneous bioavailability is 96% compared to 14% for the oral tablet.,Single dose pharmacokinetics of sumatriptan in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768259/),%,14,139886,DB00669,Sumatriptan
,7768259,apparent volume of distribution,Sumatriptan has a large apparent volume of distribution (170 l) and an elimination half-life of 2 h.,Single dose pharmacokinetics of sumatriptan in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768259/),l,170,139887,DB00669,Sumatriptan
,7768259,elimination half-life,Sumatriptan has a large apparent volume of distribution (170 l) and an elimination half-life of 2 h.,Single dose pharmacokinetics of sumatriptan in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768259/),h,2,139888,DB00669,Sumatriptan
,23992438,area under the curve [AUC]0-∞,"Although the extent of systemic exposure over 14 hours was similar following Breath Powered delivery of 16-mg sumatriptan powder and 20-mg liquid nasal spray (area under the curve [AUC]0-∞ 64.9 ng*hour/mL vs 61.1 ng*hour/mL), sumatriptan powder, despite a 20% lower dose, produced 27% higher peak exposure (Cmax 20.8 ng/mL vs 16.4 ng/mL) and 61% higher exposure in the first 30 minutes compared with the nasal spray (AUC0-30 minutes 5.8 ng*hour/mL vs 3.6 ng*hour/mL).",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[h·ng] / [ml],64.9,143644,DB00669,Sumatriptan
,23992438,area under the curve [AUC]0-∞,"Although the extent of systemic exposure over 14 hours was similar following Breath Powered delivery of 16-mg sumatriptan powder and 20-mg liquid nasal spray (area under the curve [AUC]0-∞ 64.9 ng*hour/mL vs 61.1 ng*hour/mL), sumatriptan powder, despite a 20% lower dose, produced 27% higher peak exposure (Cmax 20.8 ng/mL vs 16.4 ng/mL) and 61% higher exposure in the first 30 minutes compared with the nasal spray (AUC0-30 minutes 5.8 ng*hour/mL vs 3.6 ng*hour/mL).",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[h·ng] / [ml],61.1,143645,DB00669,Sumatriptan
,23992438,Cmax,"Although the extent of systemic exposure over 14 hours was similar following Breath Powered delivery of 16-mg sumatriptan powder and 20-mg liquid nasal spray (area under the curve [AUC]0-∞ 64.9 ng*hour/mL vs 61.1 ng*hour/mL), sumatriptan powder, despite a 20% lower dose, produced 27% higher peak exposure (Cmax 20.8 ng/mL vs 16.4 ng/mL) and 61% higher exposure in the first 30 minutes compared with the nasal spray (AUC0-30 minutes 5.8 ng*hour/mL vs 3.6 ng*hour/mL).",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[ng] / [ml],20.8,143646,DB00669,Sumatriptan
,23992438,Cmax,"Although the extent of systemic exposure over 14 hours was similar following Breath Powered delivery of 16-mg sumatriptan powder and 20-mg liquid nasal spray (area under the curve [AUC]0-∞ 64.9 ng*hour/mL vs 61.1 ng*hour/mL), sumatriptan powder, despite a 20% lower dose, produced 27% higher peak exposure (Cmax 20.8 ng/mL vs 16.4 ng/mL) and 61% higher exposure in the first 30 minutes compared with the nasal spray (AUC0-30 minutes 5.8 ng*hour/mL vs 3.6 ng*hour/mL).",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[ng] / [ml],16.4,143647,DB00669,Sumatriptan
,23992438,AUC0-30 minutes,"Although the extent of systemic exposure over 14 hours was similar following Breath Powered delivery of 16-mg sumatriptan powder and 20-mg liquid nasal spray (area under the curve [AUC]0-∞ 64.9 ng*hour/mL vs 61.1 ng*hour/mL), sumatriptan powder, despite a 20% lower dose, produced 27% higher peak exposure (Cmax 20.8 ng/mL vs 16.4 ng/mL) and 61% higher exposure in the first 30 minutes compared with the nasal spray (AUC0-30 minutes 5.8 ng*hour/mL vs 3.6 ng*hour/mL).",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[h·ng] / [ml],5.8,143648,DB00669,Sumatriptan
,23992438,AUC0-30 minutes,"Although the extent of systemic exposure over 14 hours was similar following Breath Powered delivery of 16-mg sumatriptan powder and 20-mg liquid nasal spray (area under the curve [AUC]0-∞ 64.9 ng*hour/mL vs 61.1 ng*hour/mL), sumatriptan powder, despite a 20% lower dose, produced 27% higher peak exposure (Cmax 20.8 ng/mL vs 16.4 ng/mL) and 61% higher exposure in the first 30 minutes compared with the nasal spray (AUC0-30 minutes 5.8 ng*hour/mL vs 3.6 ng*hour/mL).",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[h·ng] / [ml],3.6,143649,DB00669,Sumatriptan
,23992438,Cmax,"Relative to the 100-mg oral tablet (Cmax 70.2 ng/mL, AUC0-∞, 308.8 ng*hour/mL) and 6-mg injection (Cmax 111.6 ng/mL, AUC0-∞ 128.2 ng*hour/mL), the peak and overall exposure following Breath Powered intranasal delivery of sumatriptan powder was substantially lower.",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[ng] / [ml],70.2,143650,DB00669,Sumatriptan
,23992438,AUC0-∞,"Relative to the 100-mg oral tablet (Cmax 70.2 ng/mL, AUC0-∞, 308.8 ng*hour/mL) and 6-mg injection (Cmax 111.6 ng/mL, AUC0-∞ 128.2 ng*hour/mL), the peak and overall exposure following Breath Powered intranasal delivery of sumatriptan powder was substantially lower.",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[h·ng] / [ml],308.8,143651,DB00669,Sumatriptan
,23992438,Cmax,"Relative to the 100-mg oral tablet (Cmax 70.2 ng/mL, AUC0-∞, 308.8 ng*hour/mL) and 6-mg injection (Cmax 111.6 ng/mL, AUC0-∞ 128.2 ng*hour/mL), the peak and overall exposure following Breath Powered intranasal delivery of sumatriptan powder was substantially lower.",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[ng] / [ml],111.6,143652,DB00669,Sumatriptan
,23992438,AUC0-∞,"Relative to the 100-mg oral tablet (Cmax 70.2 ng/mL, AUC0-∞, 308.8 ng*hour/mL) and 6-mg injection (Cmax 111.6 ng/mL, AUC0-∞ 128.2 ng*hour/mL), the peak and overall exposure following Breath Powered intranasal delivery of sumatriptan powder was substantially lower.",Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992438/),[h·ng] / [ml],128.2,143653,DB00669,Sumatriptan
,15601811,time to initial disintegration,"For nonencapsulated versus encapsulated tablets, the mean (+/- standard deviation) time to initial disintegration (6 +/- 5 minutes vs 8 +/- 5 minutes) and time to complete disintegration (18 +/- 14 minutes vs 16 +/- 7 minutes) were comparable.",In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601811/),min,6,147301,DB00669,Sumatriptan
,15601811,time to initial disintegration,"For nonencapsulated versus encapsulated tablets, the mean (+/- standard deviation) time to initial disintegration (6 +/- 5 minutes vs 8 +/- 5 minutes) and time to complete disintegration (18 +/- 14 minutes vs 16 +/- 7 minutes) were comparable.",In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601811/),min,8,147302,DB00669,Sumatriptan
,15601811,time to complete disintegration,"For nonencapsulated versus encapsulated tablets, the mean (+/- standard deviation) time to initial disintegration (6 +/- 5 minutes vs 8 +/- 5 minutes) and time to complete disintegration (18 +/- 14 minutes vs 16 +/- 7 minutes) were comparable.",In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601811/),min,18,147303,DB00669,Sumatriptan
,15601811,time to complete disintegration,"For nonencapsulated versus encapsulated tablets, the mean (+/- standard deviation) time to initial disintegration (6 +/- 5 minutes vs 8 +/- 5 minutes) and time to complete disintegration (18 +/- 14 minutes vs 16 +/- 7 minutes) were comparable.",In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601811/),min,16,147304,DB00669,Sumatriptan
greater,2544284,bioavailability,"The bioavailability is greater than 54% in dog, but lower in rat.",The kinetics of 14C-GR43175 in rat and dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544284/),%,54,148481,DB00669,Sumatriptan
,15171943,absolute recovery,The absolute recovery was 92.6% for sumatriptan and 95.6% for the internal standard.,High performance liquid chromatographic method for the determination of sumatriptan with fluorescence detection in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171943/),%,92.6,151123,DB00669,Sumatriptan
,15171943,absolute recovery,The absolute recovery was 92.6% for sumatriptan and 95.6% for the internal standard.,High performance liquid chromatographic method for the determination of sumatriptan with fluorescence detection in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171943/),%,95.6,151124,DB00669,Sumatriptan
,7902233,Oral absorption,"Oral absorption of sumatriptan is essentially complete in dogs and rabbits, but only approximately 50% in rat.",Disposition of sumatriptan in laboratory animals and humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902233/),%,50,151395,DB00669,Sumatriptan
,7902233,Bioavailabilities,"Bioavailabilities are species dependent (14, 23, 37, and 58% in humans, rabbits, rats, and dogs) reflecting differing degrees of first-pass metabolism.",Disposition of sumatriptan in laboratory animals and humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902233/),%,14,151396,DB00669,Sumatriptan
,7902233,Bioavailabilities,"Bioavailabilities are species dependent (14, 23, 37, and 58% in humans, rabbits, rats, and dogs) reflecting differing degrees of first-pass metabolism.",Disposition of sumatriptan in laboratory animals and humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902233/),%,23,151397,DB00669,Sumatriptan
,7902233,Bioavailabilities,"Bioavailabilities are species dependent (14, 23, 37, and 58% in humans, rabbits, rats, and dogs) reflecting differing degrees of first-pass metabolism.",Disposition of sumatriptan in laboratory animals and humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902233/),%,37,151398,DB00669,Sumatriptan
,7902233,Bioavailabilities,"Bioavailabilities are species dependent (14, 23, 37, and 58% in humans, rabbits, rats, and dogs) reflecting differing degrees of first-pass metabolism.",Disposition of sumatriptan in laboratory animals and humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902233/),%,58,151399,DB00669,Sumatriptan
,7902233,Elimination half-lives,"Elimination half-lives of sumatriptan are approximately 1 hr in rats and rabbits, and approximately 2 hr in dogs and humans.",Disposition of sumatriptan in laboratory animals and humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902233/),h,1,151400,DB00669,Sumatriptan
,7902233,Elimination half-lives,"Elimination half-lives of sumatriptan are approximately 1 hr in rats and rabbits, and approximately 2 hr in dogs and humans.",Disposition of sumatriptan in laboratory animals and humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902233/),h,2,151401,DB00669,Sumatriptan
,22406349,peak plasma concentration (C(max)),The peak plasma concentration (C(max)) after 0.3h of 5mg/kg oral dose of almotriptan was determined to be 69.85 ng/mL.,"LC-ESI-MS/MS determination of in vivo metabolites of almotriptan in rat plasma, urine and feces: application to pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406349/),[ng] / [ml],69.85,159980,DB00669,Sumatriptan
,19703372,t(max),"Following intranasal delivery, median t(max) was 20 min with both doses compared with 10 min after the subcutaneous dose.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),min,20,165421,DB00669,Sumatriptan
,19703372,t(max),"Following intranasal delivery, median t(max) was 20 min with both doses compared with 10 min after the subcutaneous dose.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),min,10,165422,DB00669,Sumatriptan
,19703372,C(max),"Mean +/- SD values for C(max) were 96 +/- 25, 11 +/- 7 and 16 +/- 6 ng/ml for subcutaneous, intranasal 10 mg and intranasal 20 mg formulations, respectively.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),[ng] / [ml],96,165423,DB00669,Sumatriptan
,19703372,C(max),"Mean +/- SD values for C(max) were 96 +/- 25, 11 +/- 7 and 16 +/- 6 ng/ml for subcutaneous, intranasal 10 mg and intranasal 20 mg formulations, respectively.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),[ng] / [ml],11,165424,DB00669,Sumatriptan
,19703372,C(max),"Mean +/- SD values for C(max) were 96 +/- 25, 11 +/- 7 and 16 +/- 6 ng/ml for subcutaneous, intranasal 10 mg and intranasal 20 mg formulations, respectively.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),[ng] / [ml],16,165425,DB00669,Sumatriptan
,10637423,limits of detection (LOD),The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),[pg] / [ml],250,185085,DB00669,Sumatriptan
,10637423,limits of detection (LOD),The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),[pg] / [ml],100,185086,DB00669,Sumatriptan
,10637423,signal-to-noise ratio,The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),,3,185087,DB00669,Sumatriptan
,19438727,drug delivery,"The mean drug delivery of Zelrix I and II was 6.11 mg (confidence intervals [CI] 5.33-6.88) and 6.09 mg (CI 5.52-6.66), respectively.",Zelrix: a novel transdermal formulation of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438727/),mg,6.11,191937,DB00669,Sumatriptan
,19438727,drug delivery,"The mean drug delivery of Zelrix I and II was 6.11 mg (confidence intervals [CI] 5.33-6.88) and 6.09 mg (CI 5.52-6.66), respectively.",Zelrix: a novel transdermal formulation of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438727/),mg,6.09,191938,DB00669,Sumatriptan
,32573795,time to maximum plasma concentration,"Ubrogepant median time to maximum plasma concentration was delayed (3 hours [range: 1-5 hours] vs 1.5 hours [range: 1-4 hours]), mean maximum plasma concentration was reduced by 24% (coefficient of variation: 37.4%) when ubrogepant was coadministered with sumatriptan (n = 29) compared with ubrogepant administered alone (N = 30).",Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32573795/),h,3,192931,DB00669,Sumatriptan
,32573795,time to maximum plasma concentration,"Ubrogepant median time to maximum plasma concentration was delayed (3 hours [range: 1-5 hours] vs 1.5 hours [range: 1-4 hours]), mean maximum plasma concentration was reduced by 24% (coefficient of variation: 37.4%) when ubrogepant was coadministered with sumatriptan (n = 29) compared with ubrogepant administered alone (N = 30).",Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32573795/),h,1.5,192932,DB00669,Sumatriptan
,32573795,time to maximum plasma concentration,"Sumatriptan area under the curve and maximum plasma concentration showed no significant change when sumatriptan was coadministered with ubrogepant (n = 29), but the sumatriptan time to maximum plasma concentration was delayed (1 hour [range: 0.5-5 hours] vs 3 hours [range: 0.5-6 hours].",Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32573795/),h,1,192933,DB00669,Sumatriptan
,32573795,time to maximum plasma concentration,"Sumatriptan area under the curve and maximum plasma concentration showed no significant change when sumatriptan was coadministered with ubrogepant (n = 29), but the sumatriptan time to maximum plasma concentration was delayed (1 hour [range: 0.5-5 hours] vs 3 hours [range: 0.5-6 hours].",Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32573795/),h,3,192934,DB00669,Sumatriptan
,22289113,area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],56.68,193499,DB00669,Sumatriptan
,22289113,area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],78.49,193500,DB00669,Sumatriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],56.68,193501,DB00669,Sumatriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],22.39,193502,DB00669,Sumatriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],78.49,193503,DB00669,Sumatriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],22.27,193504,DB00669,Sumatriptan
,27020929,m/,"A triple-quadrupole mass spectrometer equipped with an electrospray source in the positive mode was set up in the selective reaction monitoring mode to detect the ion transitions m/z 231.67 → m/z 185.07, m/z 296.70 → m/z 157.30, m/z 354.80 → m/z 215.00, and m/z 336.80 → m/z 97.94 for naproxen, sumatriptan, aceclofenac, and naratriptan, respectively.",Development and validation of an LC-ESI-MS/MS method for the simultaneous quantification of naproxen and sumatriptan in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020929/),,354.80,198149,DB00669,Sumatriptan
>,22818944,extraction recovery,Matrix effect was assessed by post-column analyte infusion and the extraction recovery was >95.0% across four quality control levels for both the analytes.,Challenges in the simultaneous quantitation of sumatriptan and naproxen in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22818944/),%,95.0,205117,DB00669,Sumatriptan
,9160269,t1/2,The pharmacokinetic parameters showed short t1/2 (range 1.14-1.9 h) either after intravenous (i.v.) or oral (p.o.) administration and high total body clearance (CL) after the p.o. dose both probably due to extensive and rapid metabolism of the parent drugs as suggested by the low values for bioavailability (range 13.4-22.8%).,"A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9160269/),h,1.14-1.9,205119,DB00669,Sumatriptan
,9160269,bioavailability,The pharmacokinetic parameters showed short t1/2 (range 1.14-1.9 h) either after intravenous (i.v.) or oral (p.o.) administration and high total body clearance (CL) after the p.o. dose both probably due to extensive and rapid metabolism of the parent drugs as suggested by the low values for bioavailability (range 13.4-22.8%).,"A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9160269/),%,13.4-22.8,205120,DB00669,Sumatriptan
,12190330,C(max),"Mean C(max) after a 20mg intranasal dose is approximately 13.1 to 14.4 ng/mL, with median time to C(max) approximately 1 to 1.75 hours.",Clinical pharmacokinetics of intranasal sumatriptan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190330/),[ng] / [ml],13.1 to 14.4,207737,DB00669,Sumatriptan
,12190330,time to C(max),"Mean C(max) after a 20mg intranasal dose is approximately 13.1 to 14.4 ng/mL, with median time to C(max) approximately 1 to 1.75 hours.",Clinical pharmacokinetics of intranasal sumatriptan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190330/),h,1 to 1.75,207738,DB00669,Sumatriptan
,12190330,elimination phase half-life,"The elimination phase half-life is approximately 2 hours, consistent with administration by other routes.",Clinical pharmacokinetics of intranasal sumatriptan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190330/),h,2,207739,DB00669,Sumatriptan
,9004457,half-life,2. Following intravenous administration sumatriptan was eliminated from plasma with a half-life of about 1.1 h.,"Absorption, pharmacokinetics and metabolism of 14C-sumatriptan following intranasal administration to the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004457/),h,1.1,208815,DB00669,Sumatriptan
,9004457,elimination half-life after,The elimination half-life after the second peak was estimated as being about 4 h.,"Absorption, pharmacokinetics and metabolism of 14C-sumatriptan following intranasal administration to the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004457/),h,4,208816,DB00669,Sumatriptan
,9004457,bioavailability,"The bioavailability is estimated as about 30%, for the period 0-6 h.","Absorption, pharmacokinetics and metabolism of 14C-sumatriptan following intranasal administration to the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004457/),%,30,208817,DB00669,Sumatriptan
,32579251,polydispersity index (PDI),The optimization of experiments led to nanoparticles with 101 nm mean diameter and polydispersity index (PDI) of 0.27.,"Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579251/),,0.27,213274,DB00669,Sumatriptan
,32579251,drug,The drug entrapment efficiency (EE) for optimized nanoparticle was found to be 91.00%.,"Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579251/),%,91.00,213275,DB00669,Sumatriptan
,32579251,entrapment efficiency (EE),The drug entrapment efficiency (EE) for optimized nanoparticle was found to be 91.00%.,"Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579251/),%,91.00,213276,DB00669,Sumatriptan
,11293557,times to first measurable plasma concentration,"Absorption was assessed by calculating the area under the plasma concentration-time curve from dosing to 2 hours after dosing (AUC2) and the times to first measurable plasma concentration, 10 ng/mL, 20 ng/mL, and maximum plasma concentration.",Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11293557/),[ng] / [ml],10,218537,DB00669,Sumatriptan
,11293557,times to first measurable plasma concentration,"Absorption was assessed by calculating the area under the plasma concentration-time curve from dosing to 2 hours after dosing (AUC2) and the times to first measurable plasma concentration, 10 ng/mL, 20 ng/mL, and maximum plasma concentration.",Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11293557/),[ng] / [ml],20,218538,DB00669,Sumatriptan
,10844134,steady-state plasma concentrations,"Using an infusion concentration of 50 mg/ml citalopram, steady-state plasma concentrations of approximately 0.3 mcM citalopram were maintained for 15 days.",Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10844134/),mcM,0.3,218902,DB00669,Sumatriptan
,28290023,globule size,SME and SSME were transparent and stable with mean globule size 38±20 nm and zeta potential between -35 to -55 mV.,Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290023/),nm,38,219389,DB00669,Sumatriptan
,28290023,zeta potential,SME and SSME were transparent and stable with mean globule size 38±20 nm and zeta potential between -35 to -55 mV.,Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290023/),m,55,219390,DB00669,Sumatriptan
,28290023,Brain/blood uptake ratios,"Brain/blood uptake ratios at 0.5 hour following IV administration of SME and intranasal administrations of SME, SMME, and SSS were found to be 0.20, 0.50, 0.60, and 0.26, respectively, suggesting effective transport of drug following intranasal administration of microemulsions.",Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290023/),,0.20,219391,DB00669,Sumatriptan
,28290023,Brain/blood uptake ratios,"Brain/blood uptake ratios at 0.5 hour following IV administration of SME and intranasal administrations of SME, SMME, and SSS were found to be 0.20, 0.50, 0.60, and 0.26, respectively, suggesting effective transport of drug following intranasal administration of microemulsions.",Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290023/),,0.50,219392,DB00669,Sumatriptan
,28290023,Brain/blood uptake ratios,"Brain/blood uptake ratios at 0.5 hour following IV administration of SME and intranasal administrations of SME, SMME, and SSS were found to be 0.20, 0.50, 0.60, and 0.26, respectively, suggesting effective transport of drug following intranasal administration of microemulsions.",Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290023/),,0.60,219393,DB00669,Sumatriptan
,28290023,Brain/blood uptake ratios,"Brain/blood uptake ratios at 0.5 hour following IV administration of SME and intranasal administrations of SME, SMME, and SSS were found to be 0.20, 0.50, 0.60, and 0.26, respectively, suggesting effective transport of drug following intranasal administration of microemulsions.",Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290023/),,0.26,219394,DB00669,Sumatriptan
,24191774,oral bioavailability,"Sumatriptan succinate has oral bioavailability of 15% and undergoes hepatic metabolism, hence it is suitable for nasal administration.","Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24191774/),%,15,219438,DB00669,Sumatriptan
,24191774,absolute bioavailability,"Optimized formulation, F7 has shown absolute bioavailability, which was found to be 164.70%.","Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24191774/),%,164.70,219439,DB00669,Sumatriptan
,24191774,Drug targeting index,Drug targeting index for brain tissues was found to be 1.866.,"Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24191774/),,1.866,219440,DB00669,Sumatriptan
,2544285,absolute bioavailability,The drug was rapidly absorbed after oral dosing and had a mean absolute bioavailability of 14% due at least in part to first-pass metabolism.,Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544285/),%,14,228671,DB00669,Sumatriptan
,2544285,plasma clearance,"GR43175 had a high mean plasma clearance (1313 ml/min), the majority of which was due to non-renal clearance and a large volume of distribution (2351).",Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544285/),[ml] / [min],1313,228672,DB00669,Sumatriptan
,2544285,volume of distribution,"GR43175 had a high mean plasma clearance (1313 ml/min), the majority of which was due to non-renal clearance and a large volume of distribution (2351).",Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544285/),,2351,228673,DB00669,Sumatriptan
,2544285,half-lives,"The mean half-lives were 1.7 h and 2.3 h after intravenous and oral doses, respectively.",Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544285/),h,1.7,228674,DB00669,Sumatriptan
,2544285,half-lives,"The mean half-lives were 1.7 h and 2.3 h after intravenous and oral doses, respectively.",Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544285/),h,2.3,228675,DB00669,Sumatriptan
,1653134,oral bioavailabilities,"Following absorption there was some first-pass metabolism resulting in oral bioavailabilities of 37, 58 and 23% in rat, dog and rabbit, respectively.","Preclinical studies on the anti-migraine drug, sumatriptan. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653134/),%,37,233580,DB00669,Sumatriptan
,1653134,oral bioavailabilities,"Following absorption there was some first-pass metabolism resulting in oral bioavailabilities of 37, 58 and 23% in rat, dog and rabbit, respectively.","Preclinical studies on the anti-migraine drug, sumatriptan. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653134/),%,58,233581,DB00669,Sumatriptan
,1653134,oral bioavailabilities,"Following absorption there was some first-pass metabolism resulting in oral bioavailabilities of 37, 58 and 23% in rat, dog and rabbit, respectively.","Preclinical studies on the anti-migraine drug, sumatriptan. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653134/),%,23,233582,DB00669,Sumatriptan
,1653134,half-life,"In all species, circulating sumatriptan was cleared rapidly by metabolic and renal clearance with a half-life of 1-2 h.","Preclinical studies on the anti-migraine drug, sumatriptan. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653134/),h,1-2,233583,DB00669,Sumatriptan
,15992123,plasma half-life,"With a plasma half-life of 6 h, very high oral bioavailability of 63-74% and higher lipophilicity than sumatriptan, naratriptan exhibits a distinct clinical therapeutic profile.",Naratriptan: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992123/),h,6,234722,DB00669,Sumatriptan
,15992123,oral bioavailability,"With a plasma half-life of 6 h, very high oral bioavailability of 63-74% and higher lipophilicity than sumatriptan, naratriptan exhibits a distinct clinical therapeutic profile.",Naratriptan: a review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992123/),%,63-74,234723,DB00669,Sumatriptan
,15200736,percentage C(max),"Other measures including AUC(0-0.5) (AUC to 30 min post-dose), times to achieve sumatriptan concentrations of 5 and 10 ng/mL, and mean percentage C(max) 15, 20 and 30 min post-dose demonstrate an observable improvement in rate of drug absorption for the new form of sumatriptan compared with conventional tablets.",Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200736/),min,15,236558,DB00669,Sumatriptan
,15200736,percentage C(max),"Other measures including AUC(0-0.5) (AUC to 30 min post-dose), times to achieve sumatriptan concentrations of 5 and 10 ng/mL, and mean percentage C(max) 15, 20 and 30 min post-dose demonstrate an observable improvement in rate of drug absorption for the new form of sumatriptan compared with conventional tablets.",Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200736/),min,20,236559,DB00669,Sumatriptan
,15200736,percentage C(max),"Other measures including AUC(0-0.5) (AUC to 30 min post-dose), times to achieve sumatriptan concentrations of 5 and 10 ng/mL, and mean percentage C(max) 15, 20 and 30 min post-dose demonstrate an observable improvement in rate of drug absorption for the new form of sumatriptan compared with conventional tablets.",Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200736/),min,30,236560,DB00669,Sumatriptan
,1659437,Cmax,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),[ng] / [ml],120,260754,DB00669,Sumatriptan
,1659437,Cmax,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),[ng] / [ml],126,260755,DB00669,Sumatriptan
,1659437,tmax,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),h,4.5,260756,DB00669,Sumatriptan
,1659437,tmax,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),h,3.0,260757,DB00669,Sumatriptan
,1659437,AUC,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),[h·ng] / [ml],580,260758,DB00669,Sumatriptan
,1659437,AUC,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),[h·ng] / [ml],566,260759,DB00669,Sumatriptan
,1659437,"t 1/2,z","The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),h,1.9,260760,DB00669,Sumatriptan
,1659437,"t 1/2,z","The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),h,1.8,260761,DB00669,Sumatriptan
,24641436,maximum mean serum concentration,Pharmacokinetic studies have shown that iontophoretic delivery of sumatriptan achieves detectable plasma concentrations 15 min after activation with a maximum mean serum concentration of 22 ng/ml.,Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24641436/),[ng] / [ml],22,273135,DB00669,Sumatriptan
,24641436,pain-free rate,The pain-free rate at 2 h postdose was 18% of patients applying the sumatriptan patch versus 9% using the placebo (p = 0.0092).,Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24641436/),%,18,273136,DB00669,Sumatriptan
,24641436,pain-free rate,The pain-free rate at 2 h postdose was 18% of patients applying the sumatriptan patch versus 9% using the placebo (p = 0.0092).,Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24641436/),,9,273137,DB00669,Sumatriptan
